NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice.

IF 9.4 1区 医学 Q1 HEMATOLOGY
Junlei Hou, Shuanglong Xie, Jianbao Gao, Tao Jiang, Enjian Zhu, Xuezhi Yang, Zheng Jin, Haixia Long, Anmei Zhang, Fei Yang, Lujing Wang, Haoran Zha, Qingzhu Jia, Bo Zhu, Xinxin Wang
{"title":"NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice.","authors":"Junlei Hou, Shuanglong Xie, Jianbao Gao, Tao Jiang, Enjian Zhu, Xuezhi Yang, Zheng Jin, Haixia Long, Anmei Zhang, Fei Yang, Lujing Wang, Haoran Zha, Qingzhu Jia, Bo Zhu, Xinxin Wang","doi":"10.1186/s40164-024-00511-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cancer is the leading cause of death among older adults. Although the integration of immunotherapy has revolutionized the therapeutic landscape of cancer, the complex interactions between age and immunotherapy efficacy remain incompletely defined. Here, we aimed to elucidate the relationship between aging and immunotherapy resistance.</p><p><strong>Methods: </strong>Flow cytometry was performed to evaluate the infiltration of immune cells in the tumor microenvironment (TME). In vivo T cell proliferation, cytotoxicity and migration assays were performed to evaluate the antitumor capacity of tumor antigen-specific CD8<sup>+</sup> T cells in mice. Real-time quantitative PCR (qPCR) was used to investigate the expression of IFN-γ-associated gene and natural killer (NK)-associated chemokine. Adoptive NK cell transfer was adopted to evaluate the effects of NK cells from young mice in overcoming the immunotherapy resistance of aged mice.</p><p><strong>Results: </strong>We found that elderly patients with advanced non-small cell lung cancer (aNSCLC) aged ≥ 75 years exhibited poorer progression-free survival (PFS), overall survival (OS) and a lower clinical response rate after immunotherapy. Mechanistically, we showed that the infiltration of NK cells was significantly reduced in aged mice compared to younger mice. Furthermore, the aged NK cells could also suppress the activation of tumor antigen-specific CD8<sup>+</sup> T cells by inhibiting the recruitment and activation of CD103<sup>+</sup> dendritic cells (DCs). Adoptive transfer of NK cells from young mice to aged mice promoted TME remodeling, and reversed immunotherapy resistance.</p><p><strong>Conclusion: </strong>Our findings revealed the decreased sensitivity of elderly patients to immunotherapy, as well as in aged mice. This may be attributed to the reduction of NK cells in aged mice, which inhibits CD103<sup>+</sup> DCs recruitment and its CD86 expression and ultimately leads to immunotherapy resistance.</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"13 1","pages":"48"},"PeriodicalIF":9.4000,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11080179/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental Hematology & Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40164-024-00511-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cancer is the leading cause of death among older adults. Although the integration of immunotherapy has revolutionized the therapeutic landscape of cancer, the complex interactions between age and immunotherapy efficacy remain incompletely defined. Here, we aimed to elucidate the relationship between aging and immunotherapy resistance.

Methods: Flow cytometry was performed to evaluate the infiltration of immune cells in the tumor microenvironment (TME). In vivo T cell proliferation, cytotoxicity and migration assays were performed to evaluate the antitumor capacity of tumor antigen-specific CD8+ T cells in mice. Real-time quantitative PCR (qPCR) was used to investigate the expression of IFN-γ-associated gene and natural killer (NK)-associated chemokine. Adoptive NK cell transfer was adopted to evaluate the effects of NK cells from young mice in overcoming the immunotherapy resistance of aged mice.

Results: We found that elderly patients with advanced non-small cell lung cancer (aNSCLC) aged ≥ 75 years exhibited poorer progression-free survival (PFS), overall survival (OS) and a lower clinical response rate after immunotherapy. Mechanistically, we showed that the infiltration of NK cells was significantly reduced in aged mice compared to younger mice. Furthermore, the aged NK cells could also suppress the activation of tumor antigen-specific CD8+ T cells by inhibiting the recruitment and activation of CD103+ dendritic cells (DCs). Adoptive transfer of NK cells from young mice to aged mice promoted TME remodeling, and reversed immunotherapy resistance.

Conclusion: Our findings revealed the decreased sensitivity of elderly patients to immunotherapy, as well as in aged mice. This may be attributed to the reduction of NK cells in aged mice, which inhibits CD103+ DCs recruitment and its CD86 expression and ultimately leads to immunotherapy resistance.

NK 细胞转移克服了老年小鼠对 PD-(L)1 疗法的抵抗力。
背景:癌症是导致老年人死亡的主要原因。尽管免疫疗法的整合彻底改变了癌症的治疗格局,但年龄与免疫疗法疗效之间复杂的相互作用仍未完全明确。在此,我们旨在阐明衰老与免疫疗法耐药性之间的关系:方法:采用流式细胞术评估肿瘤微环境(TME)中免疫细胞的浸润情况。进行体内 T 细胞增殖、细胞毒性和迁移试验,以评估小鼠体内肿瘤抗原特异性 CD8+ T 细胞的抗肿瘤能力。实时定量 PCR(qPCR)用于研究 IFN-γ 相关基因和自然杀伤(NK)相关趋化因子的表达。采用采纳NK细胞转移法评估年轻小鼠的NK细胞在克服老年小鼠免疫治疗耐药性方面的效果:结果:我们发现,年龄≥75岁的晚期非小细胞肺癌(aNSCLC)老年患者在接受免疫治疗后的无进展生存期(PFS)、总生存期(OS)和临床反应率均较低。从机理上讲,我们发现与年轻小鼠相比,老年小鼠的NK细胞浸润明显减少。此外,衰老的NK细胞还能通过抑制CD103+树突状细胞(DCs)的募集和活化来抑制肿瘤抗原特异性CD8+T细胞的活化。将年轻小鼠的NK细胞收养转移到老年小鼠体内可促进TME重塑,并逆转免疫治疗耐药性:我们的研究结果表明,老年患者和老年小鼠对免疫疗法的敏感性降低。结论:我们的研究结果表明,老年患者以及老年小鼠对免疫疗法的敏感性降低,这可能是由于老年小鼠体内的 NK 细胞减少,从而抑制了 CD103+ DCs 的招募及其 CD86 的表达,最终导致免疫疗法耐药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
12.60
自引率
7.30%
发文量
97
审稿时长
6 weeks
期刊介绍: Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信